Encorafenib

468 interactions 398 cited references

Also sold as: Braftovi Braftovi®

About Encorafenib

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the bod… Read the full Encorafenib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Atazanavir Posaconazole Ranolazine Piperaquine Doravirine Pimozide

36 Contraindicated 392 Major 40 Moderate

All (468) Contraindicated (36) Major (392) Moderate (40)

Major

Encorafenib Conivaptan Vaprisol Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions, reduced sensitive CYP3A4 substrate exp... Details Encorafenib Crizotinib Xalkori Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Cyclobenzaprine Amrix Increased risk of QT interval prolongation Details Encorafenib Cyclosporine Atopica Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Dabrafenib Tafinlar Increased risk of QT interval prolongation Details Encorafenib Daridorexant Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Darifenacin Enablex Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Darunavir Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions, reduced sensitive CYP3A4 substrate exp... Details Encorafenib Defactinib Reduced defactinib exposure and reduced efficacy of defactinib Details Encorafenib Degarelix Firmagon Increased risk of QT interval prolongation Details Encorafenib Delamanid Increased risk of QT interval prolongation Details Encorafenib Desflurane Suprane An increased risk of QT interval prolongation Details Encorafenib Desipramine Norpramin Increased risk of QT interval prolongation Details Encorafenib Desogestrel Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Dexmedetomidine Dexased Increased risk of cardiac arrhythmias Details Encorafenib Dienogest Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Diltiazem Cardizem Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Domperidone Increased risk of QT interval prolongation Details Encorafenib Donepezil Adlarity Increased risk of QT interval prolongation Details Encorafenib Dordaviprone An increased risk of QT interval prolongation, reduced dordaviprone exposure and reduced efficacy of dordaviprone Details Encorafenib Doxepin Prudoxin Increased risk of QT interval prolongation Details Encorafenib Droperidol Increased risk of QT interval prolongation Details Encorafenib Drospirenone Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Duvelisib Copiktra Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Ebastine Increased risk of QT interval prolongation Details Encorafenib Ebola Zaire Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Efavirenz Increased risk of QT interval prolongation Details Encorafenib Eletriptan Relpax Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Elinzanetant Lynkuet Reduced elinzanetant exposure and reduced efficacy of elinzanetant Details Encorafenib Elvitegravir Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Entrectinib Rozlytrek Reduced entrectinib exposure, reduced efficacy of entrectinib and an increased risk of QT interval prolongation Details Encorafenib Enzalutamide Xtandi Reduced enzalutamide exposure, reduced efficacy of enzalutamide, reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Eplerenone Inspra Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Eribulin Halaven Increased risk of QT interval prolongation Details Encorafenib Erythromycin Erythrocin Stearate Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Escitalopram Lexapro Increased risk of QT interval prolongation Details Encorafenib Estetrol Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Estradiol Delestrogen Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Ethinyl Estradiol Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Ethynodiol Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.